Evidence map›Paper›PMID 39177745›Full record

ArticleRheumatology and therapy2024

Clinical and Ultrasonographic Remission in Bio-naïve and Bio-failure Patients with Rheumatoid Arthritis at 24 Weeks of Upadacitinib Treatment: The UPARAREMUS Real-Life Study.

Andrea Picchianti Diamanti, Maria Sofia Cattaruzza, Simonetta Salemi, Roberta Di Rosa, Giorgio Sesti, Chiara De Lorenzo, Gloria Maria Felice, Bruno Frediani, Caterina Baldi, Maria Sole Chimenti and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Observational
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Andrea Picchianti DiamantiDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, S. Andrea University Hospital, 00189, Rome, Italy. andrea.picchiantidiamanti@uniroma1.it.
Maria Sofia CattaruzzaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, 00185, Rome, Italy.
Simonetta SalemiDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, S. Andrea University Hospital, 00189, Rome, Italy.
Roberta Di RosaDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, S. Andrea University Hospital, 00189, Rome, Italy.
Giorgio SestiDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, S. Andrea University Hospital, 00189, Rome, Italy.
Chiara De LorenzoDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, S. Andrea University Hospital, 00189, Rome, Italy.
Gloria Maria FeliceDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, S. Andrea University Hospital, 00189, Rome, Italy.
Bruno FredianiDepartment of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Viale Mario Bracci, 53100, Siena, Italy.
Caterina BaldiDepartment of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Viale Mario Bracci, 53100, Siena, Italy.
Maria Sole ChimentiDepartment of System Medicine, Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, 00133, Rome, Italy.
Arianna D'AntonioDepartment of System Medicine, Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, 00133, Rome, Italy.
Gloria CrepaldiAcademic Rheumatology Centre, Department of Clinical and Biological Science, University of Turin, AO Mauriziano Torino, 10128, Turin, Italy.
Michele Maria LuchettiClinica Medica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy.
Valentino PaciClinica Medica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy.
Alen ZabottiRheumatology Clinic, Department of Medicine, University of Udine, c/o Azienda Sanitaria Universitaria Friuli Centrale, 33100, Udine, Italy.
Ivan GiovanniniRheumatology Clinic, Department of Medicine, University of Udine, c/o Azienda Sanitaria Universitaria Friuli Centrale, 33100, Udine, Italy.
Marco CanzoniASL Rome 1 UOSD Reumatologia, Ospedale Nuovo Regina Margherita, 00153, Rome, Italy.
Giandomenico SebastianiU.O.C. Reumatologia, A.O. San Camillo-Forlanini, Rome, Italy.
Chiara SciroccoU.O.C. Reumatologia, A.O. San Camillo-Forlanini, Rome, Italy.
Carlo PerriconeRheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Bruno Laganà *Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, S. Andrea University Hospital, 00189, Rome, Italy.
Annamaria Iagnocco *Academic Rheumatology Centre, Department of Clinical and Biological Science, University of Turin, AO Mauriziano Torino, 10128, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionClinical remission is the main target in the management of patients with rheumatoid arthritis (RA). However, several authors found synovitis in patients with RA in clinical remission at ultrasonography (US). Upadacitinib is a selective Janus kinase 1 inhibitor that achieved significantly higher remission rates than adalimumab and abatacept in patients with RA. Here we present the 24-week data of the UPAdacitinib Rheumatoid Arthritis REmission UltraSonography (UPARAREMUS) study.

methodsThis is a longitudinal multicenter observational study, enrolling bio-naïve and bio-inadequate responder patients affected by RA. The primary endpoint was the proportion of patients achieving both clinical and US remission at week 24. The proportion of patients achieving clinical remission with different composite indexes at week 12 and 24 was also evaluated. US of four target joints (wrists and second metacarpophalangeal bilaterally) was performed at baseline and weeks 12/24, and US remission was defined as the absence of power Doppler (PD) signal ≥ 2 in one target joint, or PD ≥ 1 in two target joints.

resultsAfter 12 weeks and 24 weeks, 40% and 63.6% of patients achieved US plus clinical remission. The following parameters were associated with US plus clinical remission: being bio-naïve and having a shorter disease duration, although at multivariate analysis significant odds ratio (OR) was found only for being bio-naïve.

conclusionsUPARAREMUS is the first study evaluating the efficacy of upadacitinib in reaching both clinical and US remission in patients with RA. At 24 weeks, 63.6% of patients reached the primary endpoint, the only baseline associated parameter was being bio-naïve.

Indexed as

Clinical remissionJAK inhibitorsUltrasonographic remissionUpadacitinib

Identifiers

PMID39177745
PMCPMC11422397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.